Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortizatization of Intangibles (2020 - 2025)

Insight Molecular Diagnostics' Amortizatization of Intangibles history spans 6 years, with the latest figure at $7000.0 for Q1 2025.

  • For Q1 2025, Amortizatization of Intangibles fell 68.18% year-over-year to $7000.0; the TTM value through Sep 2025 reached $29000.0, down 67.05%, while the annual FY2024 figure was $88000.0, 0.0% changed from the prior year.
  • Amortizatization of Intangibles for Q1 2025 was $7000.0 at Insight Molecular Diagnostics, down from $22000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q2 2021 and bottomed at $7000.0 in Q1 2025.
  • The 5-year median for Amortizatization of Intangibles is $22000.0 (2023), against an average of $425647.1.
  • The largest annual shift saw Amortizatization of Intangibles skyrocketed 4781.82% in 2021 before it plummeted 97.75% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $990000.0 in 2021, then decreased by 17.98% to $812000.0 in 2022, then plummeted by 97.29% to $22000.0 in 2023, then changed by 0.0% to $22000.0 in 2024, then crashed by 68.18% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Amortizatization of Intangibles are $7000.0 (Q1 2025), $22000.0 (Q4 2024), and $22000.0 (Q3 2024).